Single shot aims to stop liver cancer recurrence
NCT ID NCT06526338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether a single injection of IP-001, given right after standard liver cancer ablation or surgery plus ablation, can help keep the cancer from coming back. About 126 adults with intermediate to high risk of recurrence will be followed for at least two years. The study compares IP-001 plus standard care against standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IP-001 injection
- What this could lead to
- If successful, this could offer a new way to delay or prevent liver cancer from coming back after standard ablation treatment.
- What could go wrong
- This is an early phase 2 trial with only 126 people, so results may not apply to everyone. The treatment is a single injection, and its long-term safety and effectiveness are not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Louisville
RECRUITINGLouisville, Kentucky, 40202, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?